In case you missed it, a new survey from CancerCare of more than 1,300 breast, colon, lung and prostate cancer patients diagnosed within the past five years found that the vast majority had not heard of clinical pathways. And even after the term was defined, fewer than half claimed to be familiar with the term.
As health care payers seek to transition to new, value-based payment models, clinical pathways are one strategy payers and providers are using in their efforts to contain costs and promote evidence-based care. Clinical pathways can encompass a wide range of activities – from care protocols that help reduce infection or prevent unnecessary visits to the emergency department, to those that seek to promote more efficient treatment decision-making.
Check out a few highlights below and view the findings here.
- Ninety-seven percent of respondents considered their physicians recommendations to be very or somewhat important in helping them decide on a treatment plan.
- The majority of respondents indicated that if their doctor based a treatment plan recommendation on a pathway, they would have important information needs.
- CancerCare says, “According to these findings there is a critical need for significant information flow from providers to patients regarding the basis for and impact of treatment recommendations.”
Holly Campbell Holly Campbell is a deputy vice president of public affairs at PhRMA focusing on the cost and value of medicines. Prior to joining PhRMA, Holly worked for large and small public relations firms where she provided strategic communications counsel, media relations and partnership expertise to health care and pharmaceutical clients. In her free time, she enjoys taking barre classes, trying new restaurants and spending time with Boss and Poppy, her rescue pups.
Topics: Value, cancer, Value-Driven Health Care, The Value Collaborative
Medicare Monday (100)
340B Spotlight (41)
Cost & Consequence (0)
